Sign up USA
Proactive Investors - Run By Investors For Investors

Marinus Pharmaceuticals Inc shares soar on early study results

Enrollment is continuing in the study with top-line data expected in mid-2017
Marinus Pharmaceuticals Inc shares soar on early study results
The data comes from initial CDKL5 patients enrolled in an ongoing Phase 2 open-label study, the company said

Shares in Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shot up almost 40% as it posted positive clinical study findings.

The data comes from initial CDKL5 patients enrolled in an ongoing Phase 2 open-label study evaluating its ganaxolone candidate as a treatment for orphan, genetic disorders.

CDKL5 is a severe, rare genetic disorder that results in early-onset, difficult-to-control seizures.

Enrollment is continuing in the study with top-line data expected in mid-2017.

“We are encouraged by the results in these difficult-to-treat pediatric patients,” said Dr. Jaakko Lappalainen, vice president of clinical development at the company.

“Concurrent with completing this study, we will be evaluating the potential for breakthrough therapy and applying for orphan drug designation with the United States Food and Drug Administration.

"CDKL5 pediatric epilepsy may prove to be an attractive and efficient path for ganaxolone and we look forward to evaluating results from the final patients enrolled in this cohort of the study.”

Shares in New York are at US$1.61 - an increase of 38.79% at the time of writing.



Register here to be notified of future MRNS Company articles
View full MRNS profile View Profile

Marinus Timeline

Related Articles

Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use